CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(USD ($)) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2012		Sep. 30, 2011
Cash flows from operating activities:
Net loss before non-controlling interest	$ (2,911)		$ (6,796)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	23		52
Amortization of intangible assets	66		0
Accretion of convertible note discount	183		0
Amortization of deferred financing costs	115		0
Stock-based compensation expense	449		144
Loss on disposal of property and equipment	2		118
Assignment of common stock of Medicsight	0		(4)
Gain on sale of loan receivable - related party	0		(81)
(Increase)/decrease in assets:
Accounts receivable	77		(280)
Other receivables - related party	0		47
Proceeds from release of security deposits	180		0
Prepaid expenses and other current assets	260		(212)
Inventory	36		0
Increase / (decrease) in liabilities:
Accounts payable	41		11
Accrued expenses	(299)		(315)
Other payables	(40)		14
Net cash used in operating activities	(1,818)		(7,302)
Cash flows from investing activities:
Purchase of property and equipment	(12)		(4)
Purchase of shares of Medicsight Ltd.	(14)		0
Purchase of intangible asset	(200)		0
Repayment of Dunamis Capital loan	0		1,100
Receipts from sale of Moneygate	0		401
Receipts of deferred consideration for sale of assets	0		370
Receipts from sale of Medicsight Ltd's stock	0		110
Net cash (used in) / provided by investing activities	(226)		1,977
Cash flows from financing activities:
Cash paid in lieu of fractional shares in reverse/forward split	(5)		0
Proceeds from issuance of convertible note	3,500		0
Payments for convertible note issuance costs	(372)		0
Net cash provided by financing activities	3,123		0
Effects of exchange rates on cash and cash equivalents	81		427
Net change in cash and cash equivalents	1,160		(4,898)
Cash and cash equivalents, beginning of period	3,704	[1]	8,434
Cash and cash equivalents, end of period	4,864		3,536
Supplemental cash disclosures:
Cash paid for interest on convertible note	23		0
Supplemental non-cash disclosures (investing and financing activities):
Stock issued for services in connection with issuance of convertible note	315		0
Warrants issued in connection with acquisition of intangible assets	800		0
Warrants issued in connection with issuance of convertible note	500		0
Beneficial conversion on convertible note	500		0
Intangible asset contributed by non-controlling interest	819		0
Stock issued for purchase of Medicsight ordinary shares	$ 141		$ 0

[1] Derived from audited financial information